Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy

Conclusion:
Tiotropium + olodaterol Respimat® FDC is a cost-effective bronchodilator in the maintenance treatment of COPD for the Italian health care system.

Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Selya-Hammer, C., Gonzalez-Rojas Guix, N., Baldwin, M., Ternouth, A., Miravitlles, M., Rutten-van Mölken, M., Goosens, L. M. A., Buyukkaramikli, N., Acciai, V. Tags: Original Research Source Type: research